Abraxis BioScience, Inc., an integrated, global biopharmaceutical company, announced the filing of its Form 10 registration statement in connection with the proposed plan to separate its proprietary business Abraxis Oncology and Abraxis Research (the new Abraxis BioScience) from its hospital-based business Abraxis Pharmaceutical Products (APP).

The information statement outlines the operations of the proprietary business and can be found at the SEC's Web site under the company name "New Abraxis, Inc." The company will apply to list the securities on the NASDAQ Global Market under the symbol "ABII." Following is a link to the information statement on the SEC's Web site: http://www.sec.gov/Archives/edgar/data/1409012/000119312507177626/ dex991.htm.